Gold bars to be exempt from tariffs, White House clarifies
Serina Therapeutics, Inc. (NASDAQ:SER), a $53.7 million market cap biotech company, saw its Chief Scientific Officer Randall Moreadith sell 6,500 shares of common stock on July 14, 2025, for a total of $32,565. The shares were sold at prices ranging from $5.00 to $5.91, amid a challenging week that saw the stock decline nearly 13%. According to InvestingPro analysis, the stock appears overvalued at current levels.
According to a Form 4 filing with the Securities and Exchange Commission, the same day, Moreadith also exercised options to purchase 6,500 shares of Serina Therapeutics common stock at a price of $0.06 per share, for a total value of $390. These options were fully vested and exercisable. Despite recent price weakness, analyst targets range from $11 to $15, suggesting potential upside. Track insider transactions and access 10+ additional exclusive insights with InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.